# Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC

> **NCT04152486** · PHASE3 · UNKNOWN · sponsor: **London School of Hygiene and Tropical Medicine** · enrollment: 20426 (actual)

## Conditions studied

- Ebola Virus Disease

## Interventions

- **BIOLOGICAL:** Ad26.ZEBOV, MVA-BN-Filo vaccine

## Key facts

- **NCT ID:** NCT04152486
- **Lead sponsor:** London School of Hygiene and Tropical Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11-14
- **Primary completion:** 2022-01-31
- **Final completion:** 2022-02-28
- **Target enrollment:** 20426 (ACTUAL)
- **Last updated:** 2021-11-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04152486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04152486, "Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT04152486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*